Year: 2024
Type: article
Abstract: Kinpeygo (budesonide) is a corticosteroid‐based therapy approved for the treatment of adults with rapidly progressing primary immunoglobulin A nephropathy. This article discusses its mode of action, efficacy and adverse effects.
Source: Prescriber
DOI: 10.1002/psb.2151
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402416765